CollPlant Biotechnologies Ltd. (CLGN)
| Market Cap | 7.64M -72.7% |
| Revenue (ttm) | 318,000 -86.8% |
| Net Income | -12.51M |
| EPS | -9.32 |
| Shares Out | 1.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,084 |
| Open | 4.150 |
| Previous Close | 4.135 |
| Day's Range | 3.950 - 4.200 |
| 52-Week Range | 2.637 - 22.899 |
| Beta | 0.76 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue mat... [Read more]
Financial Performance
In 2025, CollPlant Biotechnologies's revenue was $2.37 million, an increase of 360.39% compared to the previous year's $515,000. Losses were -$11.49 million, -30.83% less than in 2024.
Financial StatementsNews
LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology
Rehovot, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary LightSolver Ltd.
CollPlant announces $3.7M private placement
CollPlant (CLGN) Biotechnologies announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the company’s ordinary shares and unregistered warrant...
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT
Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN...
CollPlant subsidiary files U.S. provisional patent for photonic computing
CollPlant (CLGN) Biotechnologies subsidiary LightSolver has filed a provisional patent application with the USPTO for an invention that significantly expands the capabilities of its all-optical, laser...
LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations
CollPlant Advances its Photonic Computing Strategy Through LightSolver's Growing IP Portfolio REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announce...
CollPlant reports Q2 non-GAAP EPS ($1.69) vs. ($2.30) last year
Reports Q2 revenue $108K vs. $179K last year. CEO Yehiel Tal commented: “The acquisition of LightSolver marks CollPlant’s (CLGN) strategic entry into high-performance computing (HPC) and photonics com...
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Sept. 30, 2026 /PRNew...
CollPlant Biotechnologies Earnings release: Q2 2026
CollPlant Biotechnologies released its Q2 2026 earnings on September 30, 2026, summarizing the period's financial results.
LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
Peer-reviewed study published by ACM: LightSolver's LPU architecture demonstrated significantly lower projected time-to-solution, compared to state-of-the-art algorithms running on a GPU REHOVOT, Isra...
CollPlant regains Nasdaq compliance
CollPlant (CLGN) Biotechnologies announced the receipt of a formal notification from The Nasdaq Stock Market that the company has regained compliance with Listing Rule 5550(a)(2), which requires the c...
CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq confirms the Company satisfies continued listing criteria under Listing Rule 5550(a)(2), officially closing the compliance matter Follows the recent completion of the LightSolver acquisition, m...
CollPlant Biotechnologies Transcript: Investor update
A strategic acquisition introduces a disruptive all-optical computing platform targeting the $89B HPC market, with a performance-driven deal structure and strong customer validation, including Boeing. Commercialization is underway, with product launch targeted for 2028.
CollPlant Biotechnologies Slides: Investor update
CollPlant Biotechnologies has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
CollPlant to Host LightSolver Investor Webinar on September 17, 2026
REHOVOT, Israel, Sept. 10, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
CollPlant appoints Shlmoni to Board of Directors
CollPlant (CLGN) Biotechnologies announced the appointment of Dr. Ruti Ben Shlomi, Chief Executive Officer and Co-Founder of LightSolve, to CollPlant’s Board of Directors, effective immediately follow...
COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technology ...
CollPlant Biotechnologies trading halted, news pending
19:50 EDT CollPlant (CLGN) Biotechnologies trading halted, news pending
CollPlant completes acquisition of LightSolver
CollPlant (CLGN) Biotechnologies announced the successful closing of its previously announced acquisition of LightSolver. As detailed in the definitive agreement announcement on August 31, 2026, the a...
COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
Technological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platform Accelerated Growth Path - The transac...
CollPlant approves reverse share split
CollPlant (CLGN) Biotechnologies announced that its Board of Directors has approved a one-for-ten reverse share split of the Company’s ordinary shares. The reverse share split is scheduled to take eff...
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
CollPlant (CLGN) Stock Soars 31% on a New Acquisition Deal with LightSolver
CollPlant stock surged on Monday after the company announced an acquisition agreement for Israeli deep-tech firm LightSolver.
CollPlant signs definitive agreement to acquire LightSolver
CollPlant (CLGN) Biotechnologies announced that it has signed a definitive agreement to acquire LightSolver. The acquisition is expected to close this week. LightSolver has developed the Laser Process...
COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
LightSolver is pioneering pure photonic computing, bringing a new computing architecture to the public markets to address the speed, energy and heat limitations of semiconductor-based computing LightS...
CollPlant Biotechnologies Registration statement: Registration filing
CollPlant Biotechnologies filed a registration statement on July 9, 2026, providing details about a securities offering with the SEC.